AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread
Description: Samples of white bread, with or without the addition of PGX fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread
Description: Samples of white bread, with or without the addition of PGX fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mashed Potatoes
Description: samples of mashed potatoes, with or without the addition of soluble fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mashed Potatoes
Description: samples of mashed potatoes, with or without the addition of soluble fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Muffins
Description: Samples of muffins, with or without the addition of PGX fibre blend
Study NCT04242472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based Mobile Health intervention
Description: Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
Study NCT00279461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo in arm A and Vitamin D in arm B
Description: Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
Study NCT00279461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D 3 for arm A ,and matching placebo for arm B
Description: Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
Study NCT04520542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Application
Description: Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
Study NCT04415164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xueshuantong lyophilized powder
Description: Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
Study NCT04415164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
Study NCT04415164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Guidelines-based standard care
Description: Guidelines-based standard care for acute ischemic stroke
Study NCT04415164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidelines-based standard care
Description: Guidelines-based standard care for acute ischemic stroke
Study NCT00287534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: oral
Study NCT00287534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study NCT04467567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
Description: SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
Study NCT03699618 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF
Description: Standard of care treatment with anti-VEGF only
Study NCT03699618 — intervention group
Intervention type: OTHER
Intervention: Hemorrhage displacement + Anti-VEGF
Description: Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
Study NCT02748356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Description: Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
Study NCT02099890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Study NCT02099890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetation Protein Powder
Study NCT02099890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InflanNox
Study NCT02099890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-oxidant Network
Study NCT02099890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella
Study NCT03258294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin(Circadin®)
Study NCT03258294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT03656068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500mg BID
Description: Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
Study NCT00002875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT03939468 — intervention group
Intervention type: DEVICE
Intervention: DES+DCB
Description: A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
Study NCT03884751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T Cells
Description: CAR-GPC3 T Cells injection
Study NCT01049425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 4 cycles, intravenous use, day 1 every three weeks
Study NCT01049425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 4 cycles, intravenous infusion, day 1 every three weeks
Study NCT01049425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
Study NCT01049425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 6 cycles, intravenous infusion, day 1 every 3 weeks
Study NCT01049425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 6 cycles, intravenous infusion, day one every three weeks
Study NCT01715987 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: 300mg, oral daily for two years
Study NCT01715987 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: 0.5mg oral daily for two years.
Study NCT05361031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis (VM202)
Description: Intramuscular injections
Study NCT02742844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APZ2 application
Description: Application of IMP on patients wound.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL
Description: ISL 0.75 mg capsule taken by mouth.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR
Description: DOR 100 mg tablet taken by mouth.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DOR/ISL
Description: 100 mg DOR/0.75 mg ISL FDC taken by mouth.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo capsule matched to ISL taken by mouth.
Study NCT04233216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to DOR
Description: Placebo tablet matched to DOR taken by mouth.
Study NCT00002875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT03529604 — intervention group
Intervention type: OTHER
Intervention: Saliva sampling
Description: Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
Study NCT00002875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002875 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00002875 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT02040103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression
Description: All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
Study NCT03325816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is administered intravenously
Study NCT03325816 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA0-Tyr3-Octreotate
Description: 177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Given IV
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin
Description: Given IV
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Given orally
Study NCT00651261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03529604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
Study NCT03529604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC
Description: High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
Study NCT04382456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acacia gum
Description: Two sachets (à 5 g) in the morning and two sachets in the evening, reconstituted in 120 ml water and stirred until fully dissolved to be taken 10 minutes before meals.
Study NCT02656797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Amphotericin-B 0.4% liposomal gel
Description: Topical Amphotericin-B 0.4% liposomal gel
Study NCT04388033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell/Tumor Fusion Vaccine
Description: Vaccine is derived from the participants dendritic cells and tumor cells.
Study NCT04388033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-12
Description: Given subcutaneously at dose of 6ug twice for interval of one hour.
Study NCT04388033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Following concomitant radiation (2 Gy/day x 30 days) and TMZ-chemotherapy (75 mg/m2/ day x 42 days) , maintenance chemotherapy with TMZ will be administered at 150-200 mg/m2/day for 5 days in each 28-day cycle.
Study NCT01877759 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Mesenchymal stem cell
Description: Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow \& umbilical cord , IN 6 divided doses , at interval of 1 week .
Study NCT05213078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive teaching intervention
Study NCT05213078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02656797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Amphotericin-B 0.4% liposomal gel
Description: Topical Amphotericin-B 0.4% liposomal gel
Study NCT03646786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality tests
Description: The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~1. 10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~2. 10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~3. Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe
Study NCT05213078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00162383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debrisoquine
Study NCT00162383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephenytoin
Study NCT00162383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Study NCT00162383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02273141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006, Day Before-Only Dosing
Description: The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
Study NCT02273141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP+MS, Day Before-Only Dosing
Description: The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone acetate
Description: ocular medication administration
Study NCT00651261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone acetate
Description: ocular medication administration
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Second-generation tyrosine kinase inhibitor
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally twice daily.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB057643
Description: INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
Study NCT02959437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Study NCT00864032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg twice daily
Study NCT01059760 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fasting First
Description: 28±4 hours of water-only fasting followed by 28±4 hours fed
Study NCT01059760 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fed First
Description: 28± 4 hours fed followed by 28± 4 hours of fasting
Study NCT01736228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL
Description: two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
Study NCT02046980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gufoni
Study NCT02046980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration
Study NCT02046980 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT01388816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muffins
Description: Samples of muffins, with or without the addition of PGX fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hot Breakfast Cereal
Description: Samples of hot breakfast cereal without the addition of soluble fibre blend
Study NCT01898026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hot Breakfast Cereal
Description: Samples of hot breakfast cereal without the addition of soluble fibre blend
Study NCT03750175 — intervention group
Intervention type: OTHER
Intervention: Plasma circulating DNA analysis
Description: Clinical utility of ctDNA analysis for treatment decision
Study NCT00417989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed Paradigm REAL-Time System
Description: Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
Study NCT03169530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: \~15 gm daily of beer, wine, or spirits for \~6 years
Study NCT01032200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Given orally
Study NCT01032200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03145519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vasofix Certo Catheter
Description: Placement of IV-catheter
Study NCT03145519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiVein Catheter
Description: Placement of IV-catheter
Study NCT00672100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 5 ml Ropivacaine via interscalene injection
Study NCT00672100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 10 ml Ropivacaine via interscalene injection
Study NCT00672100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 20 ml Ropivacaine via interscalene injection
Study NCT02567786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with CPB
Study NCT02567786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Study NCT02567786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte
Study NCT01772381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Long acting corticosteroid
Study NCT03550014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Back Only
Description: The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.